WO1995030423A3 - Cancer treatment and metastasis prevention - Google Patents

Cancer treatment and metastasis prevention Download PDF

Info

Publication number
WO1995030423A3
WO1995030423A3 PCT/CA1995/000259 CA9500259W WO9530423A3 WO 1995030423 A3 WO1995030423 A3 WO 1995030423A3 CA 9500259 W CA9500259 W CA 9500259W WO 9530423 A3 WO9530423 A3 WO 9530423A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
drug
daltons
cancer
amount
Prior art date
Application number
PCT/CA1995/000259
Other languages
French (fr)
Other versions
WO1995030423A2 (en
Inventor
Rudolf Edgar Falk
Samuel Simon Asculai
Original Assignee
Norpharmco Inc
Rudolf Edgar Falk
Samuel Simon Asculai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/675,908 external-priority patent/US6069135A/en
Application filed by Norpharmco Inc, Rudolf Edgar Falk, Samuel Simon Asculai filed Critical Norpharmco Inc
Priority to SK1379-96A priority Critical patent/SK137996A3/en
Priority to JP7528564A priority patent/JPH09512797A/en
Priority to EP95917846A priority patent/EP0760667A1/en
Priority to KR1019960706101A priority patent/KR970702728A/en
Priority to AU24023/95A priority patent/AU696373B2/en
Publication of WO1995030423A2 publication Critical patent/WO1995030423A2/en
Publication of WO1995030423A3 publication Critical patent/WO1995030423A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

A new method for the treatment of cancer in a human particularly malignant tumors, for example those in a breast or breasts, said method comprising the steps of: (1) directly injecting into the tumour a dosage amount of a pharmaceutical composition comprising an effective amount of an anti-cancer drug and/or drug suitable for use to treat cancer (for example about 1 to about 2 mg NovantroneTM (Mitoxantrone), other chemotherapeutic agent, NSAIDs) and an effective amount of a form of hyaluronic acid, for example hyaluronic acid and/or pharmaceutically acceptable salts thereof preferably sodium hyaluronate having a molecular weight of less than 750,000 daltons (for example 150,000 - 225,000 daltons) (for example about 10 to about 20 mg sodium hyaluronate) in sterile water; and (2) administering systemically, preferably intravenously, a dosage amount of a pharmaceutical composition comprising: (i) an effective amount of a form of hyaluronic acid (for example hyaluronic acid and/or pharmaceutically acceptable salts thereof, preferably sodium hyaluronate having a molecular weight less than 750,000 daltons (for example 150,000 - 225,000 daltons) for example about 100 - 200 mg or more (because of a lack of toxicity and to reduce the side effects of any medicine (for example NSAID) administered therewith if the amount of the form of hyaluronic acid exceeds about 200 mg/70 kg person); (ii) a drug selected from the group comprising: a) a non-steroidal anti-inflammatory drug (NSAID) for example in an amount of from about 30 mg to about 100 mg (for example 30 to 60 mg of tromethanine salt of ketoralac (sold under the trade mark Toradol) and 50 to 100 mg of diclofenac or diclofenac sodium (for example sold under the trade mark Voltarol), b) an anti-cancer drug, and c) a drug suitable for use to treat cancer and combinations thereof optionally together with (iii) an anti-oxidant for example Vitamin C (in one embodiment 25 gm of Vitamin C).
PCT/CA1995/000259 1991-07-03 1995-04-28 Cancer treatment and metastasis prevention WO1995030423A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SK1379-96A SK137996A3 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
JP7528564A JPH09512797A (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
EP95917846A EP0760667A1 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
KR1019960706101A KR970702728A (en) 1994-04-29 1995-04-28 Cancer Treatment and Metastasis Prevention
AU24023/95A AU696373B2 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/675,908 US6069135A (en) 1989-09-21 1990-09-18 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
CA2,122,519 1994-04-29
CA002122519A CA2122519C (en) 1994-04-29 1994-04-29 Cancer treatment and metastasis prevention

Publications (2)

Publication Number Publication Date
WO1995030423A2 WO1995030423A2 (en) 1995-11-16
WO1995030423A3 true WO1995030423A3 (en) 1995-12-21

Family

ID=4153495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1995/000259 WO1995030423A2 (en) 1991-07-03 1995-04-28 Cancer treatment and metastasis prevention

Country Status (11)

Country Link
EP (1) EP0760667A1 (en)
JP (1) JPH09512797A (en)
KR (1) KR970702728A (en)
CN (1) CN1151118A (en)
AU (1) AU696373B2 (en)
CA (1) CA2122519C (en)
CZ (1) CZ308996A3 (en)
HU (1) HUT75868A (en)
RU (1) RU2162327C2 (en)
SK (1) SK137996A3 (en)
WO (1) WO1995030423A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2208924A1 (en) * 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
DE69833264T2 (en) * 1997-08-29 2006-09-28 Biogen Idec Ma Inc., Cambridge METHOD AND COMPOSITIONS FOR CANCER THERAPY USING INTERFERON-BETA CODING GENES
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
JP2002537255A (en) 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト Systemic use of 5-HT3 receptor antagonists for rheumatic inflammatory processes
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
EP1532434A4 (en) * 2002-07-01 2009-05-27 Univ Tufts Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
US20060003027A1 (en) * 2004-06-30 2006-01-05 Zhou James H Composition and method for reducing side effects of indole-3-carbinol and derivatives
CN103784960A (en) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 Therapeutic protocols using hyaluronan
AU2006289651B2 (en) 2005-09-07 2012-07-26 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
CA2664158C (en) 2006-09-22 2015-11-24 Kochi University Radiation sensitizer or anti-cancer chemotherapy sensitizer
KR100856114B1 (en) * 2008-04-18 2008-09-02 강지민 Sending and receiving method for sound and data of television using remote control
CN102497871B (en) 2008-11-14 2014-10-15 希斯托金公司 Extracellular matrix compositions for the treatment of cancer
FR2994846B1 (en) 2012-08-29 2014-12-26 Vivacy Lab COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE
RU2586043C1 (en) * 2014-11-12 2016-06-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Method for prevention and treatment of complications in radiation therapy of skin cancer
RU2723883C2 (en) * 2018-07-17 2020-06-18 Николай Васильевич Цугленок Method for initiating death of tumour cells with ascorbic acid and hydroside with 3-aminophthalic acid and hf- and microwave energy wave radiation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004058A2 (en) * 1989-09-21 1991-04-04 Norpharmco Inc. Treatment of conditions and disease
WO1993016732A1 (en) * 1992-02-20 1993-09-02 Norpharmco Inc. Formulations containing hyaluronic acid
WO1993016733A1 (en) * 1992-02-20 1993-09-02 Norpharmco Inc. Topical composition containing hyaluronic acid and nsaids
CA2097892A1 (en) * 1993-06-07 1994-12-07 Rudolf Edgar Falk Prevention and control of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004058A2 (en) * 1989-09-21 1991-04-04 Norpharmco Inc. Treatment of conditions and disease
WO1993016732A1 (en) * 1992-02-20 1993-09-02 Norpharmco Inc. Formulations containing hyaluronic acid
WO1993016733A1 (en) * 1992-02-20 1993-09-02 Norpharmco Inc. Topical composition containing hyaluronic acid and nsaids
CA2097892A1 (en) * 1993-06-07 1994-12-07 Rudolf Edgar Falk Prevention and control of cancer

Also Published As

Publication number Publication date
HUT75868A (en) 1997-05-28
AU696373B2 (en) 1998-09-10
JPH09512797A (en) 1997-12-22
HU9602965D0 (en) 1997-01-28
CZ308996A3 (en) 1998-01-14
CN1151118A (en) 1997-06-04
KR970702728A (en) 1997-06-10
AU2402395A (en) 1995-11-29
CA2122519A1 (en) 1995-10-30
SK137996A3 (en) 1998-08-05
WO1995030423A2 (en) 1995-11-16
RU2162327C2 (en) 2001-01-27
EP0760667A1 (en) 1997-03-12
CA2122519C (en) 2001-02-20

Similar Documents

Publication Publication Date Title
WO1995030423A3 (en) Cancer treatment and metastasis prevention
JP3256761B2 (en) Treatment of symptoms and diseases
US6346519B1 (en) Method and composition for treating arthritis
RU96122884A (en) HUMAN CANCER TREATMENT METHOD
US5614506A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
CY1111088T1 (en) PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY
NZ217483A (en) Composition for delivery of hydrophobic drugs
JP2002537333A (en) Synergistic antitumor composition
CA2240329A1 (en) Improved delivery of multiple doses of medications
KR930007441A (en) medicine
JP2002507571A (en) Antitumor composition containing a synergistic combination of anthracycline derivative and camptothecin derivative
KR960700063A (en) Potentiation of temozolomide in human tumour cells
RU95101385A (en) Products containing g-csf and tnf-binding protein
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
CA2175282A1 (en) Use of forms of hyaluronic acid (ha) for the treatment of cancer
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
JP2706371B2 (en) Auxiliary agent for cancer treatment and kit using the same
AU707467B2 (en) Nasal administration of agents for treatment of delayed onset emesis
Ryan et al. Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients
US20110117070A1 (en) Compositions and methods for treating headache
EP0338679A2 (en) Tumour necrosis factor in the treatment of bladder cancer
CA2294095C (en) Synergistically acting compositions for selectively combating tumor tissue
Link et al. Cutaneous manifestations of taxol® therapy
US5817644A (en) Targeting of dosages of medicine and therapeutic agents
JP2000513707A (en) Drug Targeting, Therapeutics and Other Glycosaminoglycans (GAGS)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95193689.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1995 464768

Country of ref document: US

Date of ref document: 19951013

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PV1996-3089

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 137996

Country of ref document: SK

Ref document number: 285042

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995917846

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995917846

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: PV1996-3089

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1996-3089

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1995917846

Country of ref document: EP